According to a new study, Tysabri significantly increases the proportion of disease-free patients with relapsing multiple sclerosis (MS) compared with placebo after two years. In the study, 942 MS patients were given either intravenous Tysabri or a placebo once every four weeks for up to 116 weeks. Researchers found that the proportion of disease-free patients was significantly higher in the Tysabri group compared with the placebo group.
Read moreAccording to new research, patients receiving optimal drug therapy after suffering a heart attack do not gain any additional benefit from taking... Read more »
Elderly people suffering from a type of heart disease called diastolic heart failure do not seem to benefit from the commonly prescribed heart... Read more »
Many COPD sufferers are underweight or malnourished, but a British study suggests that getting nutritional advice may help. Researchers found that... Read more »
Patients who have COPD may benefit from taking statin drugs, a new review of published research suggests. Scientists looked at nine studies conducted... Read more »
Poor Patient Asthmatics would take better care of their asthma if they knew how. They need help developing a good asthma action plan for themselves.... Read more »